Jazz Pharmaceuticals PLC (JAZZ) - Stock & Dividends

Jazz Pharmaceuticals plc is a biopharmaceutical company known for identifying, developing, and commercializing pharmaceutical products to meet medical needs in the United States, Europe, and globally.

The company's portfolio includes a range of products and candidates that focus on neuroscience, particularly in sleep medicine and movement disorders, as well as in oncology, with emphasis on hematologic and solid tumors.

Jazz Pharmaceuticals' flagship products in neuroscience are Xywav, an oral solution for cataplexy and excessive daytime sleepiness, Xyrem for narcolepsy, and Epidiolex for seizures associated with certain syndromes. In oncology, the company offers Zepzelca, Rylaze, Vyxeos, and Defitelio for various cancer treatments.

Moreover, Jazz Pharmaceuticals has engaged in licensing and collaboration agreements with several organizations, including Zymeworks Inc., Sumitomo Pharma Co., Ltd, and Codiak BioSciences, Inc., among others, further expanding its innovative reach in the industry.

Established in 2003, Jazz Pharmaceuticals is based in Dublin, Ireland, and continually strives to make a positive impact in healthcare. For more information, visit their website at https://www.jazzpharma.com.